Skip to main content

Virtual visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More

COVID-19 Updates

COVID-19 Updates: Get the latest on vaccine information, in-person appointments, virtual visits and more. Learn More



Texas Medical Center

Cancer and Hematology
Phone: 832-824-5667


1102 Bates Ave., Ste. 1030.15
Houston, TX 77030

Research Area

Tamra E. Ogilvie, PhD

Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine


School Education Degree Year
McMaster Stem Cell and Cancer Research Institute, McMaster University Post-doctoral Fellow 2010
Brain Tumour Research Centre, Montreal Neurological Institute, McGill University PhD Doctor of Philosophy 2006
University of Western Ontario Bachelors Bachelor of Science, Biology 2000


Organization Name Role
Manitoba Neuroscience Network Member
Neuro-Oncology Editorial Board Member
Society for Neuro-Oncology (SNO) Member
Society for Neuro-Oncology (SNO) Member, International Women and Diversity Committee

Research Statement

Dr. Tamra Ogilvie's laboratory is entirely dedicated to studying medulloblastoma (MB), the most common malignant primary pediatric brain tumor.

Her laboratory has made significant contributions to the underlying cellular and molecular mechanisms regulating MB stem cell fate decisions. Her laboratory has identified MB cells of origin (Nature, 2022), discovered central regulators of MB self-renewal (ie. Nature, 2022; Nature Communications, 2020, Molecular Oncology, 2018) and found potential diagnostic biomarkers for different MB molecular subgroups (i.e., Cancer Research, 2018).

Her lab utilizes biologically relevant mouse xenograft models where human MB cells are implanted into the cerebellum to assess the effects of gain/loss of gene function as well as small molecule inhibitors as potential therapeutics (Cancer Research, 2018, Molecular Oncology, 2018, Communications Biology, 2022). Combining multi-omics technologies such as ChIP sequencing, RNA sequencing, single cell RNA sequencing, TurboID and digital spatial profiling of brain tumor tissue with functional assessments both in vitro and in vivo, she has built a highly innovative research program in neuro-oncology and human stem cells.

Her work integrates basic and preclinical studies and is currently divided into 2 major research areas: 1) Novel regulators of Group 3 MB cell fate and 2) New therapeutic strategies for SHH MB tumors. Throughout her career, she has been continuously supported by national and international funding agencies, including grants from the Canada Research Chairs program, CIHR, NSERC, the Brain Tumor Foundation of Canada, as well as the Rally Foundation for Childhood Cancer Research and Alex’s Lemonade Stand Foundation.

As her contributions to research service have grown, so too has her commitment to equity, diversity and inclusion (EDI). She has joined multiple EDI committees, including the Society for Neuro-Oncology’s (SNO) International Women and Diversity Committee.

As a recent YMCA/YWCA Women of Distinction Award Nominee, she is particularly passionate about promoting and training women in STEM.

Selected Publications

Awards & Honors

2011-22    Canada Research Chair Tier II in Neuro-oncology & Human Stem Cells
2020     Outstanding reviewer recognition, CIHR College of Reviewers
2011     Junior Investigator Grant Panel Travel Award, Canadian Cancer Society Research Institute (CCS-RI)
2010     FHS Postdoctoral Fellow Publication Award, McMaster University
2008     NCIC (National Cancer Institute of Canada) Harold E. Johns Fellowship Award for highest ranking post-doctoral fellow in Canada, Post PhD Research Fellowship competition
2007-2010     NCIC Post PhD Research Fellowship
2002-05     CIHR Doctoral Research Award



* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.